EICHORCondition: Multiple Myeloma · Sponsor: Nantes University Hospital
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Multiple Myeloma (MM) is often associated with progression, temporary response to therapy and a high relapse rate over time resulting in a poor long-term prognosis. Because MM is classified as an incurable disease, therapeutic resistance is of great interest. However, knowledge about the biological mechanisms underlying resistance associated with MM therapies and about associated predictors remains poor. The MYRACLE cohort, a multicenter prospective cohort of patients with MM, is set up to address this limitation.
This description comes directly from the study's public registry record.
Cyrille TOUZEAU, PU · 02 40 08 32 71 · cyrille.touzeau@chu-nantes.fr
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Patient consulting due to the discovery or recurrence of MM according to international diagnostic criteria (IMWG 2014) * Patient having consented to participate in the study and his/her biocollection * Patient affiliated to or benefiting from a social security scheme or similar Exclusion Criteria: * Minors * Major under guardianship or curatorship * Protected persons. * Pregnant or breast-feeding women * Persons benefiting from the AME
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| La Roche sur Yon Hospital Departmental | La Roche-sur-Yon, France | Recruiting |
| Nantes University Hospital | Nantes, France | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03807128